

## Basic Study

## Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

Yan Li, William Lee, Zhen-Gang Zhao, Yi Liu, Hao Cui, Hao-Yu Wang

**Specialty type:** Gastroenterology and hepatology**Provenance and peer review:** Unsolicited article; Externally peer reviewed.**Peer-review model:** Single blind**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Banerjee S, India**Received:** August 30, 2023**Peer-review started:** August 30, 2023**First decision:** November 20, 2023**Revised:** December 2, 2023**Accepted:** December 25, 2023**Article in press:** December 25, 2023**Published online:** January 24, 2024**Yan Li, Zhen-Gang Zhao, Yi Liu, Hao Cui, Hao-Yu Wang**, Department of Gastroenterology, Tianjin Third Central Hospital, Tianjin 300170, China**William Lee**, Biomedical Engineering, Texas A&M University, College Station, TX 77843, United States**Corresponding author:** Yan Li and William Lee, MD, Chief Physician, Department of Gastroenterology, Tianjin Third Central Hospital, No. 83 Jintang Road, Hedong District, Tianjin 300170, China.[li13821177880@126.com](mailto:li13821177880@126.com)**Abstract****BACKGROUND**

Hepatocellular carcinoma (HCC) is an aggressive subtype of liver cancer and is one of the most common cancers with high mortality worldwide. Reprogrammed lipid metabolism plays crucial roles in HCC cancer cell survival, growth, and evolution. Emerging evidence suggests the importance of fatty acid binding proteins (FABPs) in contribution to cancer progression and metastasis; however, how these FABPs are dysregulated in cancer cells, especially in HCC, and the roles of FABPs in cancer progression have not been well defined.

**AIM**

To understand the genetic alterations and expression of FABPs and their associated cancer hallmarks and oncogenes in contributing to cancer malignancies.

**METHODS**

We used The Cancer Genome Atlas datasets of pan cancer and liver hepatocellular carcinoma (LIHC) as well as patient cohorts with other cancer types in this study. We investigated genetic alterations of FABPs in various cancer types. mRNA expression was used to determine if FABPs are abnormally expressed in tumor tissues compared to non-tumor controls and to investigate whether their expression correlates with patient clinical outcome, enriched cancer hallmarks and oncogenes previously reported for patients with HCC. We determined the protein levels of FABP5 and its correlated genes in two HCC cell lines and assessed the potential of FABP5 inhibition in treating HCC cells.

**RESULTS**

We discovered that a gene cluster including five FABP family members (*FABP4*, *FABP5*, *FABP8*, *FABP9* and *FABP12*) is frequently co-amplified in cancer. Amplification, in fact, is the most common genetic alteration for FABPs, leading to overexpression of FABPs. *FABP5* showed the greatest differential mRNA expression comparing tumor with non-tumor tissues. High *FABP5* expression correlates well with worse patient outcomes ( $P < 0.05$ ). *FABP5* expression highly correlates with enrichment of G2M checkpoint ( $r = 0.33$ ,  $P = 1.1e-10$ ), TP53 signaling pathway ( $r = 0.22$ ,  $P = 1.7e-5$ ) and many genes in the gene sets such as *CDK1* ( $r = 0.56$ ,  $P = 0$ ), *CDK4* ( $r = 0.49$ ,  $P = 0$ ), and *TP53* ( $r = 0.22$ ,  $P = 1.6e-5$ ). Furthermore, *FABP5* also correlates well with two co-expressed oncogenes *PLK1* and *BIRC5* in pan cancer especially in LIHC patients ( $r = 0.58$ ,  $P = 0$ ;  $r = 0.58$ ,  $P = 0$ ; respectively). *FABP5*<sup>high</sup> Huh7 cells also expressed higher protein levels of p53, *BIRC5*, *CDK1*, *CDK2*, and *CDK4* than *FABP5*<sup>low</sup> HepG2 cells. *FABP5* inhibition more potently inhibited the tumor cell growth in Huh7 cells than in HepG2 cells.

## CONCLUSION

We discovered that *FABP5* gene is frequently amplified in cancer, especially in HCC, leading to its significant elevated expression in HCC. Its high expression correlates well with worse patient outcome, enriched cancer hallmarks and oncogenes in HCC. *FABP5* inhibition impaired the cell viability of *FABP5*<sup>high</sup> Huh7 cells. All these support that *FABP5* is a novel therapeutic target for treating *FABP5*<sup>high</sup> HCC.

**Key Words:** Hepatocellular carcinoma; Fatty acid binding protein; Novel target; Amplification; Correlated expression

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Several recent studies reported that fatty acid binding proteins (FABPs) contribute to reprogrammed lipid metabolism and cancer progression; however, how these FABPs are dysregulated in cancer, especially in hepatocellular carcinoma (HCC), has not been carefully addressed. We discovered that a *FABP* gene cluster including *FABP5* are frequently amplified in cancer. *FABP5* is significantly upregulated in HCC and its high expression correlates well with worse patient outcomes, enrichment of top enriched cancer hallmarks involved in cell cycle progression, and two oncogenes *PLK1* and *BIRC5* in HCC. *FABP5* inhibition impaired the cell viability of *FABP5*<sup>high</sup> HCC cells. Our data supported that *FABP5* is a novel therapeutic target for treating HCC.

**Citation:** Li Y, Lee W, Zhao ZG, Liu Y, Cui H, Wang HY. Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma. *World J Clin Oncol* 2024; 15(1): 130-144

**URL:** <https://www.wjgnet.com/2218-4333/full/v15/i1/130.htm>

**DOI:** <https://dx.doi.org/10.5306/wjco.v15.i1.130>

## INTRODUCTION

Cancer cells are heavily dependent on cellular metabolism pathways for their disease malignancy and progression. Lipid metabolism has been increasingly recognized to be reprogrammed and plays crucial roles in cancer cell survival, growth, and evolution[1].

There is emerging evidence suggesting the critical roles of fatty acid binding proteins (FABPs) in contribution to cancer progression and metastasis[2,3]. FABPs are a family of chaperone proteins that bind to long-chain fatty acids, retinoids, and other hydrophobic molecules[3]. There are ten FABP genes identified in the human genome, each with restricted tissue distribution in healthy individuals. Some of the family members including *FABP4*, *FABP5*, and *FABP7* are abnormally expressed in cancer cells beyond tissue expression restriction and play important roles in cancer malignancy and progression[2,3]. *FABP4* is normally expressed in adipocytes at high levels and its expression is controlled by peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ )[4]. Accumulating evidence shows that *FABP4* plays important roles in cancer progression in multiple cancer types, including breast cancer[5], ovarian cancer[6], and colon cancer[7]. In contrast, loss of *FABP1* expression in colorectal cancer is associated with poor patient outcome[8]. *FABP5* is normally expressed in cells of epidermal origin and emerging evidence shows that it functions to regulate fatty acid trafficking, lipid metabolism and cell growth[9]. *FABP5* was found to be upregulated in many cancer types[10]. However, the mechanism leading to abnormal FABP expression in cancer is not clear and the roles of these FABPs in contributing to cancer progression have not been well defined. In this study, we aimed to investigate the genetic alterations leading to abnormal expression of FABPs in cancer and the missing links of abnormal FABP expression to cancer gene signatures and patient survival.

## MATERIALS AND METHODS

### Cells and reagents

Hepatocellular carcinoma (HCC) cell lines HepG2 and Huh7 were obtained from our laboratory for long-term storage and cultured in high glucose Dulbecco's modified Eagle medium containing 10% fetal bovine serum and 1% penicillin/streptomycin. SBFI-26 (S9957) was purchased from Selleck Chemicals (Houston, TX, United States). The antibodies against FABP5 (39926), p53 (9282), BIRC5 (2808), CDK1 (77055), CDK2 (2546), CDK4 (12790), MCL-1 (94296) and GAPDH (2118) were purchased from Cell Signaling Technology (Danvers, MA, United States). A CellTiter-Glo 2.0 cell viability assay kit (G9241) was purchased from Promega (Madison, WI, United States).

### Collection of datasets and bioinformatics analysis platforms

We performed data analysis for The Cancer Genome Atlas (TCGA) pan-cancer and liver hepatocellular carcinoma (LIHC) patient cohort through cBioPortal (<https://www.cbioportal.org/>) and a well-established web bioinformatic platform Gene Expression Profiling Interactive Analysis 2 (GEPIA2, <http://gepia2.cancer-pku.cn/#index>), developed by Zhang Lab, Peking University[11]. GEPIA2 collected RNA sequencing data of 9,736 tumors and 8,587 non-tumor samples from the TCGA and the Genotype-Tissue Expression projects.

### Identification of genetic alterations of FABP family members

To find out the genetic alterations of FABPs (*FABP1*, *FABP2*, *FABP3*, *FABP4*, *FABP5*, *FABP6*, *FABP7*, *PMP2*, *FABP9* and *FABP12*) in cancer cells, we used cBioPortal tools. We checked the frequencies of each genetic alteration using TCGA pan-cancer (70655 samples from 217 non-redundant studies) and LIHC cohort (1829 samples from eleven studies) and their correlation with *FABP5* mRNA expression and HCC cancer stages.

### Expression of FABP5 in tumor and non-tumor cells and its correlation with patient survival

We compared mRNA expression of FABPs in tumor *vs* non-tumor tissues using TCGA pan-cancer (9664 tumor tissue samples and 711 non-tumor tissue samples) and LIHC cohort (360 tumor tissue samples and 50 non-tumor tissue samples) and checked if high expression correlates with poor patient outcomes using the GEPIA2 platform.

### Correlation of FABP5 expression with cancer hallmarks and oncogenes in HCC cells

We assessed correlation of *FABP5* expression with cancer hallmarks enriched in HCC cells (G2M checkpoint and TP53 signaling) and highlighted genes within the gene sets using the GEPIA2 platform.

### Cell viability assay

The cell viability assay was performed as described in our earlier study[12]. Briefly, 2000 HepG2 or Huh7 cells per well were pre-seeded into white 96-well plates overnight. The cells were then treated with a 2-fold serial dilution of SBFI-26 (0-100  $\mu\text{mol/L}$ ). The cell viability was measured using a VICTOR Nivo Multimode Microplate Reader (PerkinElmer Health Sciences Inc, Shelton, CT, United States) at 72 h post treatment by using CellTiter-Glo 2.0 Reagent.

### Statistical and computational analysis

We performed Pearson's or Spearman's correlation test to determine whether there was a significant link between the two variables. The log-rank test was used to determine the statistical significance of gene expression in correlation with patient outcome. <sup>a</sup> $P < 0.05$ ; <sup>b</sup> $P < 0.01$ ; <sup>c</sup> $P < 0.001$ ; <sup>d</sup> $P < 0.0001$ .


## RESULTS

### FABP4, FABP5, FABP8, FABP9 and FABP12 are frequently co-amplified in cancer

We discovered that a cluster of FABP genes *FABP4*, *FABP5*, *FABP8*, *FABP9* and *FABP12* at the adjacent loci of chromosome 8, but not other FABPs located at different chromosomes, showed high frequencies of genetic alteration (3%) in the pan-cancer cohort (Figure 1A). The frequency of genetic alterations of these FABPs reaches 5%-6% in the LIHC cohort (Figure 1B). The prevalent type of alteration is amplification and co-occurrence of amplification of these genes *FABP4*, *FABP5*, *FABP8*, *FABP9* and *FABP12* is highly significant ( $P < 0.001$ ) (Figure 1C). Other genetic alterations such as mutations, structural variants and homo-deletion also occur but at much lower frequencies (Figure 1A and B).

### FABP5 and FABP4 amplifications occur at the highest frequencies in patients with prostate adenocarcinoma or HCC

Interestingly, when we checked genetic alterations of FABPs in different cancer types, we discovered that patients with prostate adenocarcinoma (PRAD) or HCC have the highest genetic alteration frequencies among others and again with genetic amplification as the prevalent type. *FABP4* showed the highest frequency in PRAD (7.9%) followed by HCC (7.8%) using TCGA pan cancer cohort, while *FABP5* showed the highest frequency in HCC (8.1%) followed by prostate PRAD (Figure 2A and C). Consistent with these, when we checked their genetic status in various liver cancer cohorts, we observed high *FABP4* alteration frequencies up to 12.5% and *FABP5* up to 12.2% in the aggressive subtype HCC (Figure 2B and D). Importantly, *FABP5* mRNA expression is much higher in the patients with *FABP5* amplification than those with *FABP5* gain, diploid, or deletion ( $P < 0.0001$ ) (Figure 2E). Moreover, HCC cases at stage II-IV showed higher



**Figure 1 Genetic alteration of FABP family members in various cancer types.** A-B: Genetic alteration of each FABP family member (*FABP1*, *FABP2*, *FABP3*, *FABP4*, *FABP5*, *FABP6*, *FABP7*, *PMP2*, *FABP9* and *FABP12*) in pan-cancer types (70655 samples from 217 non-redundant studies) (A) and in various liver

cancer subtypes (1829 samples from eleven studies) (B) using The Cancer Genome Atlas datasets. The mutation frequency for each FABP gene was shown next to the gene name; C: Co-occurrence of genetic alternation of the gene loci of FABP family members in liver cancer.

expression of *FABP5* ( $P = 0.071$ ), but not *FABP4* ( $P = 0.179$ ) (Figure 2F).

### **FABP5 and FABP4 are expressed at much higher levels in tumor tissues compared to non-tumor counterparts in HCC**

To find out whether amplification and resulting high expression of FABP family members has clinical significance in cancer, we compared their expression in tumor tissues and non-tumor controls for various cancer types (Figure 3A). Among all family members, *FABP3*, *FABP4*, and *FABP5* are expressed ubiquitously across various cancer types (Figure 3A), while *FABP1*, *FABP6*, *FABP7*, and *FABP8* are expressed selectively in restricted cancer types. In contrast, *FABP2*, *FABP9*, and *FABP12* are expressed at extremely low levels, if any (Figure 3A). *FABP1*, *FABP3*, *FABP4*, and *FABP5*, but not other family members, are selectively expressed in LIHC patients (Figure 3A and Supplementary Figure 1A), while *FABP3*, *FABP4* and *FABP5* are also selectively expressed in PRAD patients (Figure 3A and Supplementary Figure 1A). When we checked the expression of FABPs in tumor tissues compared to non-tumor controls, we found that *FABP5* is significantly upregulated in adrenocortical carcinoma (ACC), glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), brain lower-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), skin cutaneous melanoma (SKCM), and uveal melanoma (UVM), while *FABP4* is significantly upregulated only in colon adenocarcinoma (COAD), lung squamous cell carcinoma and stomach adenocarcinoma (Figure 3B). In patients with LIHC, among the selectively expressed FABPs, only *FABP5* and *FABP4* showed significant upregulation of mRNA expression in tumor tissues compared to non-tumor controls. Other FABPs, such as *FABP1* (restricted expression in normal liver), did not show differential expression in tumor and non-tumor tissues, even though it is expressed at prominent levels in patients with LIHC (Figure 3C and Supplementary Figure 1A-C). More importantly, high *FABP5* expression significantly correlates with overall patient survival ( $P = 6.6e-5$ ) and disease-free survival ( $P = 6.6e-5$ ) (Figure 3D-E). We found that high *FABP5* expression significantly correlates with overall survival not only in LIHC but also in other cancer types including ACC, GBM, KIRC, LGG, LUAD, SKCM, and UVM, where *FABP5* is found to be upregulated in tumor tissues compared to non-tumor control (Figure 3B and Supplementary Figure 1D). In contrast, high *FABP4* expression showed less significant correlation with poor overall survival ( $P = 0.047$ ) (Figure 3E). In addition, expression of other FABPs (*FABP1* and *FABP3*) expressed in LIHC, does not significantly correlate with overall survival ( $P = 0.21$  and  $0.091$ , respectively) (Supplementary Figure 1E-G). Together, these data indicate that *FABP5*, among other FABPs, is selectively upregulated in tumor tissues and its expression correlates well with poor clinical outcomes in patients with HCC.


### **High FABP5 expression selectively associated with enrichment of cancer hallmarks G2M checkpoint and TP53 signaling**

E2F targets, G2M checkpoint and DNA repair have been identified to be the top three cancer hallmarks enriched in HCC tumor cells compared to non-tumor controls[13], which supported that cell cycle and DNA repair signaling networks are critical for HCC cancer malignancies and progression. Therefore, we are interested in checking if *FABP5* overexpression correlates with enrichment of these important cancer hallmarks in HCC. We found that *FABP5* expression correlates well with G2M checkpoint gene signature ( $r = 0.33$ ,  $P = 1.1e-10$ ) (Figure 4A and B), and most of the genes in the dataset, including *ATR* ( $r = 0.35$ ,  $P = 3.9e-12$ )[13], *BRCA1* ( $r = 0.23$ ,  $P = 8.1e-6$ ), *CCNB1* ( $r = 0.61$ ,  $P = 0$ ), *CDK1* ( $r = 0.56$ ,  $P = 0$ ), *CDKN2D* ( $r = 0.37$ ,  $P = 121e-13$ ), *CHEK1* ( $r = 0.46$ ,  $P = 0$ ), *CHEK2* ( $r = 0.17$ ,  $P = 0.001$ ), *PI4KA* ( $r = 0.29$ ,  $P = 9.3e-9$ ), *PRKDC* ( $r = 0.43$ ,  $P = 1.4e-11$ ), *RPS6K1* ( $r = 0.3$ ,  $P = 3.6e-9$ ), and *YWHAH* ( $r = 0.38$ ,  $P = 5.7e-14$ ) (Figure 4C). Among these, expressions of *CCNB1* and *CDK1* showed the highest correlation with *FABP5* expression (Figure 4C). The strong *CCNB1-FABP5* correlation is observed in LIHC but also in many other cell types including COAD ( $r = 0.43$ ,  $P = 6.5e-14$ ), DLBCL ( $r = 0.54$ ,  $P = 6.5e-14$ ), KICH ( $r = 0.8$ ,  $P = 6.7e-16$ ), KIRC ( $r = 0.46$ ,  $P = 0$ ), READ ( $r = 0.36$ ,  $P = 0.00043$ ), tenosynovial giant cell tumor ( $r = 0.43$ ,  $P = 1.3e-7$ ), and UVM ( $r = 0.75$ ,  $P = 1.3e-15$ ) (Supplementary Figure 2A and B).


In an independent analysis using cBioportal platform, we found that most genes involved in cell cycle network are dysregulated with *TP53* as the top gene (Figure 4D). Therefore, we checked if *FABP5* expression is associated with expression of *TP53* and p53 signaling gene signature. We found that *FABP5* expression correlates well with *TP53* expression ( $r = 0.22$ ,  $P = 1.6e-5$ ), its signaling gene signature ( $r = 0.33$ ,  $P = 1.1e-10$ ) (Figure 5A and B), and almost half of the genes in the dataset, including *BCL2* ( $r = 0.15$ ,  $P = 0.0044$ ), *CDK2* ( $r = 0.28$ ,  $P = 6.6e-8$ ), *CDK4* ( $r = 0.49$ ,  $P = 0$ ), *E2F1* ( $r = 0.15$ ,  $P = 0.0029$ ), *PCNA* ( $r = 0.31$ ,  $P = 2.2e-9$ ), and *RB1* ( $r = 0.21$ ,  $P = 5.2e-5$ ) (Figure 5C). In an independent analysis using cBioportal platform, we found that most genes involved in TP53 signaling network are dysregulated with *TP53* as the top gene (Figure 5D).

### **High FABP5 expression correlated well with PLK1 and BIRC5 expression**

In our previous study, we demonstrated that that *PLK1*, a master regulator of cell cycle, and *BIRC5*, a multifunctional gene only expressed at G2M phase, are two important oncogenes that are highly co-expressed in HCC and the co-targeting of *PLK1* and *BIRC5* synergistically inhibited tumor growth of HCC preclinical models *in vitro* and *in vivo*[12]. To investigate the relationship between *FABP5* expression and *PLK1-BIRC5* co-expression in cancer, we first checked expression of selected FABPs together with *CCNB1*, *TP53*, *BIRC5* and *PLK1* (Figure 6A). Expression of *FABP5*, but not other FABPs including *FABP1*, *FABP3*, *FABP4* and *FABP6* appeared to be well-correlated with expression of *PLK1* and *BIRC5* across cancer types, in addition to *CCNB1* and *TP53* (Figure 6A). Consistent with our previous findings[12],





FABP5 (left panel) and FABP4 (right panel) in liver cancer at stage I-IV using TCGA datasets via GEPIA2 portal. <sup>a</sup>*P* < 0.0001; NS: Not significant.



DOI: 10.5306/wjco.v15.i1.130 Copyright ©The Author(s) 2024.

**Figure 3** Expression of FABP family members in tumor tissues and non-tumor tissue control in various cancer types. A-B: Expression of each FABP family member (FABP1, FABP2, FABP3, FABP4, FABP5, FABP6, FABP7, PMP2, FABP9 and FABP12) in tumor tissues and non-tumor tissue control in various cancer types (A) and statistical significance when comparing their expression in tumor tissues with non-tumor tissue control (B) using GEPIA2 portal; C: Higher expression of FABP4 and FABP5, but not FABP1, was observed in liver tumor tissues comparing to non-tumor tissue control; D-E: High expression levels of FABP5, but not FABP1 or FABP4, in liver cancer correlate with overall patient survival (D) and disease-free survival (E). <sup>a</sup>*P* < 0.05.





**Figure 4 Expression of FABP5 correlates with cancer hallmark G2M checkpoint and genes within.** A: FABP5 positively correlated with enrichment of cancer hallmark G2M checkpoint in patients with liver hepatocellular carcinoma (LIHC); B: Gene list included in the cancer hallmark G2M checkpoint. The genes that showed positive correlation with FABP5 are highlighted in red ( $P < 0.01$ ); C: Highlighted genes in the G2M checkpoint gene set positively correlate with FABP5 expression in patients with LIHC.  $P$  values show the statistical significance of the correlation;  $R$  values indicate the correlation coefficient; D: Altered expression of individual genes in the G2M checkpoint gene set showed in the context of signaling network. Pink bars show upregulation of gene expression.

expression of *PLK1* and *BIRC5* showed remarkable correlation in pan cancer ( $r = 0.73$ ,  $P = 0$ ) and even higher in LIHC ( $r = 0.83$ ,  $P = 0$ ) (Figure 6B and C). Expression of FABP5 also showed some correlation with *PLK1* ( $r = 0.19$ ,  $P = 0$ ) or *BIRC5* ( $r = 0.15$ ,  $P = 0$ ) in cancer and much better correlation in LIHC patient cohort ( $r = 0.58$ ,  $P = 0$ ;  $r = 0.58$ ,  $P = 0$ , respectively) (Figure 6D-G and Supplementary Figure 3A and B). These data demonstrate that FABP5 is highly correlated to the expression of *PLK1*-*BIRC5* co-expression, which is selectively in patients with HCC.

#### HCC cells with high FABP5 expression are sensitive to FABP5 inhibition

The stabilizing *TP53* mutation Y220C in Huh7 cells resulted in overexpression of p53, which is much higher than that in HepG2 cells harboring wild type *TP53* gene. Interestingly, FABP5 protein expression is also expressed at a much higher level in Huh7 cells than HepG2 cells (Figure 7A). *BIRC5*, *CDK1*, *CDK2*, and *CDK4*, but not *MCL-1*, are also expressed at much higher levels in FABP5<sup>high</sup> Huh7 cells than FABP5<sup>low</sup> HepG2 cells (Figure 7A). Huh7 cells are more sensitive to FABP5 inhibition by SBFI-26, a specific inhibitor of FABP5, than in HepG2 cells ( $IC_{50} = 89$  and  $145 \mu\text{mol/L}$ ) at 6 d upon treatment (Figure 7B and C). Long treatment for 6 d led to further inhibition of cell viability of Huh7 cells than shorter treatment for 3 d ( $IC_{50} = 89$  and  $749 \mu\text{mol/L}$ , respectively) (Figure 7D and E). This demonstrated that like many other compounds targeting regulators of cellular mechanism, the anti-tumor effect of FABP5 inhibitor SBFI-26 is a slow process, which requires time to show the anti-tumor effect. Together, these data indicate that HCC cells with high FABP5 expression are sensitive to FABP5 inhibition.

## DISCUSSION

In this study, we discovered the *FABP5* gene is frequently amplified together with other adjacent family members *FABP4*, *FABP8*, *FABP9* and *FABP12* as a gene cluster. However, only *FABP5* and *FABP4* are highly expressed in HCC patients and are significantly upregulated in tumor cells compared to non-tumor controls. Compared to *FABP4*, *FABP5* is expressed at higher levels in cancer including LIHC and more differentially expressed in tumor cells compared to non-tumor controls. Consistent with our data, Ohata *et al*[14] performed immunohistochemical staining of FABP5 for 243 paired HCC and adjacent non-tumor liver tissue samples. The study confirmed that all normal liver cells were stained negatively, while liver tumor cells can be divided into two groups, FABP5 positive (57.2%) and FABP5 negative (42.8%). Therefore, this data supports that FABP5 is overexpressed in 57.2% of patients with liver tumors. Our data of FABP5 expression in HepG2 and Huh7 cells is consistent with published data in this study as well. This study showed a positive correlation of high FABP5 expression with distant metastasis and invasion. However, Huh7 and HepG2 are both considered to be low metastatic. Our data showed that high expression of *FABP5* mRNA correlated well with G2M checkpoint ( $P = 1.1 \times 10^{-10}$ ,  $r = 0.33$ ) and *TP53* signaling in liver cancer cells ( $P = 1.7 \times 10^{-5}$ ,  $r = 0.22$ ) (Figures 4 and 5). We confirmed some of these gene expression differences involved in these two signaling networks including *CDK1*, *CDK2*, *CDK4*, and *BIRC5* by western blotting in FABP5 low expressing HepG2 cells and FABP5-high expressing Huh7 cells (Figure 7A). The hotspot mutation Y220C of *TP53* gene results in its decreased DNA binding and reduced p53 tumor suppressor function, leading to cancer progression[15-17]. This may explain that Huh7 cells carrying *TP53* Y220C mutation grow much faster than hepG2 cells with wild type *TP53* (cell doubling time, 24 and 48 h, respectively). Therefore, it is possible that the *TP53* genetic status affects the cell proliferation and expression of FABP5, which requires further validation.






Figure 5 Expression of *FABP5* correlates with cancer hallmark TP53 signaling and genes within. A: *FABP5* positively correlated with enrichment

of cancer hallmark TP53 signaling in patients with liver hepatocellular carcinoma; B: Gene list included in TP53 signaling. The genes that showed positive correlation with *FABP5* are highlighted in red; C: Highlighted genes in the TP53 signaling gene set positively correlate with *FABP5* expression. *P* values show the statistical significance of the correlation; *R* values show the correlation coefficient; D: Altered expression of individual genes in the TP53 signaling gene set shown in the context of signaling network. Pink bars show upregulation of gene expression.



**Figure 6** Expression of *FABP5* correlates with *PLK1* and *BIRC5* expression in pan cancer and liver cancer. A: Expression of *FABP5* and other FABP family members as well as several highlighted genes *CCNB1*, *TP53*, *BIRC5* and *PLK1* in each cancer type using GEPIA2 portal; B and C: *FABP5* expression positively correlated with expression of *BIRC5* at pan cancer (B) and liver cancer (C); D and E: *FABP5* expression positively correlated with expression of *PLK1* at pan cancer (D) and liver cancer (E); F and G: *BIRC5* expression positively correlated with expression of *PLK1* at pan cancer (F) and liver cancer (G). *P* values show the statistical significance of the correlation; *R* values show the correlation coefficient.



DOI: 10.5306/wjco.v15.i1.130 Copyright ©The Author(s) 2024.

**Figure 7 Huh7 cells are sensitive to FABP5 inhibition by SBFI-26.** A: Western blot shows the expression of FABP5, p53, and other proteins in Huh7 and HepG2 cells; B: 3-dose (0, 50 and 100  $\mu\text{mol/L}$ ) cell viability assay shows SBFI-26 inhibited the cell viability of hepatocellular carcinoma (HCC) cell lines Huh7 and HepG2 cells post treatment for 6 d; C: 8-dose (2-fold serial doses up to 100  $\mu\text{mol/L}$ ) cell viability assay showed SBFI-26 inhibited the cell viability of HCC cell lines post treatment for 6 d; D: 3-dose (0, 50 and 100  $\mu\text{mol/L}$ ) cell viability assay shows SBFI-26 inhibited the cell viability of Huh7 cells in time-dependent manner; E: 8-dose cell viability assay showed SBFI-26 inhibited the cell viability of Huh7 cells at 3- and 6-d post treatment; NS: Not significant.

Furthermore, the correlation of *FABP5* expression with poor patient survival is more significant than that of *FABP4* expression. These data suggest *FABP5* is the predominant gene across FABPs that are dysregulated in cancer, and it is the most important member that contributes significantly to cancer malignancy and progression, especially in patients with HCC. It is interesting to find out that high *FABP5* expression correlates well with top cancer hallmarks and two oncogenes *PLK1* and *BIRC5* that were identified in HCC patients in our and other studies earlier[12,13]. These data strongly suggest that *FABP5* is a novel therapeutic target for treating HCC and provides valuable insights for potential therapeutic development in treating patients with HCC.

Small molecule inhibitors targeting FABP proteins, especially FABP4, are currently under development by multiple efforts. Early preclinical data provide evidence that targeting FABP4 by BMS309403 is promising in treating cancer for multiple cancer disease models[2,7,18]. In this study, our data suggests that FABP5 is a novel therapeutic target in patients with HCC and other cancer types. FABP5 inhibitors such as SFBI-26 are emerging and demonstrate that targeting FABP5 is feasible and promising in treating cancer[13].

We found that the gene cluster with *FABP4*, *FABP5*, *FABP8*, *FABP9*, and *FABP12* in adjacent loci in chromosome 8 are often co-amplified in many cancer types but with highest frequencies in PRAD and HCC. Amplification is the most common genetic alteration type for these FABPs. In contrast, other family members *FABP1*, *FABP2*, *FABP3*, *FABP6* and *FABP7* also showed expression in cancer, ubiquitously or selectively, but are not frequently altered at genetic level. Interestingly, not all co-amplified family members are expressed in cancer due to amplification. Only *FABP4* and *FABP5* are expressed across various cancer types, suggesting that genetic amplification itself is necessary but not sufficient for their abnormal expression in cancer. Expression of *FABP4*, as a major target of  $\text{PPAR}\gamma$ [19], has been shown to be controlled by  $\text{PPAR}\gamma$ [4], and *FABP4* has been shown to negatively regulate  $\text{PPAR}\gamma$  expression level, likely through a negative feedback signaling loop. In contrast to *FABP4*, *FABP5* has been shown to facilitate fatty-acid induced  $\text{PPAR}\gamma$  activation and downstream signaling, and activated  $\text{PPAR}\gamma$  in turn upregulates *FABP5* expression levels in prostate cancer[10]. Whether this is also the case in HCC requires further investigation. In this study, we discovered that *FABP5* is the one with greatest changes in mRNA expression across family members in patients with LIHC comparing tumor with non-tumor tissues and its expression highly correlates with poor patient outcome and enriched cancer hallmarks involved in cell cycle progression.

Dysregulated cell metabolism and cell cycle progression are key interconnecting events for cancer malignancy and progression[20]. The top three cancer hallmarks previously reported in HCC patients are E2F targets, G2M checkpoint

and DNA repair[13]. All these lead to dysregulated cell cycle progression. Interestingly, we discovered that *FABP5* expression highly correlates with top cancer hallmarks enriched in LIHC patients (G2M checkpoint), which likely drive cancer cell survival and proliferation[13]. In our previous study, we demonstrated that two oncogenes, *PLK1* and *BIRC5*, are highly co-expressed in HCC and co-targeting of *PLK1* and *BIRC5* synergistically inhibited tumor growth of HCC preclinical models *in vitro* and *in vivo*[12]. Both *PLK1* and *BIRC5* are master regulators in cell cycle, powerful in promoting cell cycle progression and inhibiting cell death[21,22]. In this study, we confirmed that *PLK1* and *BIRC5* are co-expressed in cancer including HCC. More interestingly, *FABP5* expression correlates very well with expression of *PLK1* and *BIRC5* in multiple cancer types. The strong correlation of *FABP5* with cell cycle hallmark and cell cycle master regulators suggests its critical role in contribution to cancer cell progression when overexpressed.

In addition to its upregulation and functions in tumor cells, *FABP5* is also found to be dysregulated in multiple immune cell types and can serve as a novel immune-related prognostic marker and a target of immunotherapy[23]. *FABP5* was reported to regulate mitochondrial integrity and functions as cell-intrinsic checkpoint for Treg suppressive function in tumor microenvironment[24]. However, how *FABP5* is dysregulated and the underlying mechanism in anti-tumor immunity have not been fully understood and requires further investigation.

## CONCLUSION

*FABP5* is frequently amplified in HCC, leading to its abnormal expression. High *FABP5* expression correlates well with worse patient outcome, enriched cancer hallmarks and oncogenes in HCC. Targeting *FABP5* by SBFI-26 is more effective in *FABP5*-high expressing cells than *FABP5*-low expressing cells.

## ARTICLE HIGHLIGHTS

### Research background

*FABP5* amplification can serve as a prognosis biomarker for the prediction of patient outcome and as a novel therapeutic target for treating hepatocellular carcinoma (HCC) with *FABP5* amplification.

### Research motivation

*FABP5* is frequently amplified in cancer, especially in HCC, which leads to its abnormal expression in HCC. High *FABP5* expression correlates well with worse patient outcome, enriched cancer hallmarks and oncogenes in HCC. Targeting *FABP5* by SBFI-26 is more effective in *FABP5*-high expressing cells (Huh7) than *FABP5*-low expressing cells (HepG2).

### Research objectives

*FABP4*, *FABP5*, *FABP8*, *FABP9* and *FABP12* as a gene cluster is frequently amplified in cancer, which is the most common genetic alteration for FABPs. *FABP5* is highly overexpressed in cancer and its expression correlates well with worse patient outcomes. *FABP5* expression highly correlates with enrichment of G2M checkpoint, TP53 signaling pathway, and many genes in the gene sets such as *CDK1*, *CDK4*, and *TP53*. Furthermore, *FABP5* also correlates well with two co-expressed oncogenes *PLK1* and *BIRC5* in liver hepatocellular carcinoma (LIHC) patients. *FABP5*-high expressing Huh7 cells also expressed higher protein levels of p53, *BIRC5*, *CDK1*, *CDK2*, and *CDK4* than *FABP5*-low expressing HepG2 cells. Huh7 is more sensitive to *FABP5* inhibition than HepG2 cells.

### Research methods

In this study, we accessed the public available portal of The Cancer Genome Atlas datasets of pan cancer and liver hepatocellular carcinoma LIHC by using cBioPortal and GEPIA2 portal. Based on mutation and CNA (copy number variation) datasets, we investigated genetic alterations of FABP family members in various cancer types. Based on mRNA datasets, we investigated FABP expression and their correlation with patient clinical outcome, enriched cancer hallmarks and oncogenes. For validation, we determined the protein levels of *FABP5* and its correlated genes in Huh7 and HepG2 and evaluated the potential of targeting *FABP5* in treating HCC.

### Research results

The present study aimed to understand the genetic alterations and expression of FABP family members and their associated cancer hallmarks and oncogenes in contributing to cancer malignancies, especially HCC.

### Research conclusions

Several family members including *FABP4*, *FABP5*, and *FABP7* are abnormally expressed in cancer cells beyond tissue expression restriction and play important roles in cancer malignancy and progression. However, the mechanism leading to their abnormal expression is not clear.

### Research perspectives

Reprogrammed lipid metabolism plays crucial roles in cell survival, growth, and evolution in many cancer types including HCC, an aggressive subtype of liver cancer. Fatty acid binding protein (FABP) family members including

FABP5 play important roles in contribution to cancer progression and metastasis; however, how these FABP members, especially FABP5, are dysregulated in HCC and their contribution to HCC cancer progression have not been well defined.

## ACKNOWLEDGEMENTS

We would like to thank the patients and their families who contributed to this research study. We also appreciate the availability of the TCGA dataset and the built-in analysis *via* the web-based bioinformatic platforms cBioportal and GEPIA2.

## FOOTNOTES

**Co-first authors:** Yan Li and William Lee.

**Author contributions:** Li Y conceived and designed the study; Li Y, Lee W, Zhao ZG, Liu Y, Cui H, and Wang HY performed the experiments and analyzed the data; Li Y, Lee W, Zhao ZG, Liu Y, Cui H, and Wang HY interpreted the data; Li Y and Lee W drafted the manuscript; Liu Y, Cui H, and Wang HY revised the manuscript; All authors approved the final version of the article. Lee W contributed primarily to the bioinformatics analysis and therefore Lee W and Li Y contributed equally to the study. Li Y conceived and designed the study, performed the experiments, analyzed and interpreted the data, drafted and revised the manuscript. Lee W contributed to the bioinformatics analysis, data analysis and interpretation, as well as manuscript drafting and revision. Both authors have made substantial contributions to the study and are therefore qualified as co-first authors of the paper.

**Supported by** Tianjin Key Medical Discipline Construction Project, No. TJYXZDXK-034A.

**Institutional review board statement:** This study was approved by the Institutional Review Board (IRB) of Tianjin Third Central Hospital.

**Conflict-of-interest statement:** All authors have seen and agreed with the contents of the manuscript and there is no conflict of interest to declare.

**Data sharing statement:** For this bioinformatics analysis, we acquired the TCGA data and LIHC data as well as the data for other cancer patients from cBioPortal (<https://www.cbioportal.org/>). The bioinformatic platform GEPIA2 also used the TCGA datasets for the built-in analysis. No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Yan Li 0000-0003-2602-7423; William Lee 0009-0008-2736-6025; Zhen-Gang Zhao 0000-0001-7249-4474; Yi Liu 0000-0001-8082-8868; Hao Cui 0000-0002-5629-7814; Hao-Yu Wang 0000-0001-6672-2733.

**S-Editor:** Liu JH

**L-Editor:** Filipodia

**P-Editor:** Zhang XD

## REFERENCES

- 1 **Koundouros N, Pouligiannis G.** Reprogramming of fatty acid metabolism in cancer. *Br J Cancer* 2020; **122**: 4-22 [PMID: 31819192 DOI: 10.1038/s41416-019-0650-z]
- 2 **Sun N, Zhao X.** Therapeutic Implications of FABP4 in Cancer: An Emerging Target to Tackle Cancer. *Front Pharmacol* 2022; **13**: 948610 [PMID: 35899119 DOI: 10.3389/fphar.2022.948610]
- 3 **Hotamisligil GS, Bernlohr DA.** Metabolic functions of FABPs--mechanisms and therapeutic implications. *Nat Rev Endocrinol* 2015; **11**: 592-605 [PMID: 26260145 DOI: 10.1038/nrendo.2015.122]
- 4 **Lei C, Fan B, Tian J, Li M, Li Y.** PPAR $\gamma$  regulates fabp4 expression to increase DHA content in golden pompano (*Trachinotus ovatus*) hepatocytes. *Br J Nutr* 2022; **127**: 3-11 [PMID: 33663633 DOI: 10.1017/S0007114521000775]
- 5 **Zeng J, Sauter ER, Li B.** FABP4: A New Player in Obesity-Associated Breast Cancer. *Trends Mol Med* 2020; **26**: 437-440 [PMID: 32359475 DOI: 10.1016/j.molmed.2020.03.004]
- 6 **Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrman JF, Lastra RR, Romero IL, Fiehn O, Lengyel E.** Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. *Cancer Res* 2020; **80**: 1748-1761 [PMID: 32054768 DOI: 10.1158/0008-5472.CAN-19-1999]
- 7 **Tian W, Zhang W, Zhang Y, Zhu T, Hua Y, Li H, Zhang Q, Xia M.** FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport. *Cancer Cell Int* 2020; **20**: 512 [PMID: 33088219 DOI: 10.1186/s12935-020-01582-4]

- 8 **Dum D**, Ocokoljic A, Lennartz M, Hube-Magg C, Reisch V, Höflmayer D, Jacobsen F, Bernreuther C, Lebok P, Sauter G, Luebke AM, Burandt E, Marx AH, Simon R, Clauditz TS, Minner S, Menz A, Büscheck F, Gorbokov N, Steurer S, Blessin NC, Krech T. FABP1 expression in human tumors: a tissue microarray study on 17,071 tumors. *Virchows Arch* 2022; **481**: 945-961 [PMID: [35951102](#) DOI: [10.1007/s00428-022-03394-5](#)]
- 9 **Xu B**, Chen L, Zhan Y, Marquez KNS, Zhuo L, Qi S, Zhu J, He Y, Chen X, Zhang H, Shen Y, Chen G, Gu J, Guo Y, Liu S, Xie T. The Biological Functions and Regulatory Mechanisms of Fatty Acid Binding Protein 5 in Various Diseases. *Front Cell Dev Biol* 2022; **10**: 857919 [PMID: [35445019](#) DOI: [10.3389/fcell.2022.857919](#)]
- 10 **O'Sullivan SE**, Kaczocha M. FABP5 as a novel molecular target in prostate cancer. *Drug Discov Today* 2020 [PMID: [32966866](#) DOI: [10.1016/j.drudis.2020.09.018](#)]
- 11 **Tang Z**, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. *Nucleic Acids Res* 2019; **47**: W556-W560 [PMID: [31114875](#) DOI: [10.1093/nar/gkz430](#)]
- 12 **Li Y**, Zhao ZG, Luo Y, Cui H, Wang HY, Jia YF, Gao YT. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma. *World J Gastroenterol* 2020; **26**: 4786-4801 [PMID: [32921957](#) DOI: [10.3748/wjg.v26.i32.4786](#)]
- 13 **Zhu W**, Zhang Q, Liu M, Yan M, Chu X, Li Y. Identification of DNA repair-related genes predicting pathogenesis and prognosis for liver cancer. *Cancer Cell Int* 2021; **21**: 81 [PMID: [33516217](#) DOI: [10.1186/s12935-021-01779-1](#)]
- 14 **Ohata T**, Yokoo H, Kamiyama T, Fukai M, Aiyama T, Hatanaka Y, Hatanaka K, Wakayama K, Orimo T, Kakisaka T, Kobayashi N, Matsuno Y, Taketomi A. Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition. *Cancer Med* 2017; **6**: 1049-1061 [PMID: [28374947](#) DOI: [10.1002/cam4.1020](#)]
- 15 **Boettcher S**, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkovic K, Piccioni F, Root DE, Rucker FG, Flamand Y, Neuberger D, Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. *Science* 2019; **365**: 599-604 [PMID: [31395785](#) DOI: [10.1126/science.aax3649](#)]
- 16 **Dearth LR**, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, Yi SY, Brachmann RK. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. *Carcinogenesis* 2007; **28**: 289-298 [PMID: [16861262](#) DOI: [10.1093/carcin/bgl132](#)]
- 17 **Liu X**, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, Fersht AR. Small molecule induced reactivation of mutant p53 in cancer cells. *Nucleic Acids Res* 2013; **41**: 6034-6044 [PMID: [23630318](#) DOI: [10.1093/nar/gkt305](#)]
- 18 **Farrell M**, Fairfield H, Karam M, D'Amico A, Murphy CS, Falank C, Pistofidi RS, Cao A, Marinac CR, Dragon JA, McGuinness L, Gartner CG, Iorio RD, Jachimowicz E, DeMambro V, Vary C, Reagan MR. Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling. *Elife* 2023; **12** [PMID: [36880649](#) DOI: [10.7554/eLife.81184](#)]
- 19 **Tontonoz P**, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, Tempst P, Spiegelman BM. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. *Nucleic Acids Res* 1994; **22**: 5628-5634 [PMID: [7838715](#) DOI: [10.1093/nar/22.25.5628](#)]
- 20 **Icard P**, Fournel L, Wu Z, Alifano M, Lincet H. Interconnection between Metabolism and Cell Cycle in Cancer. *Trends Biochem Sci* 2019; **44**: 490-501 [PMID: [30655165](#) DOI: [10.1016/j.tibs.2018.12.007](#)]
- 21 **Chiappa M**, Petrella S, Damia G, Broggin M, Guffanti F, Ricci F. Present and Future Perspective on PLK1 Inhibition in Cancer Treatment. *Front Oncol* 2022; **12**: 903016 [PMID: [35719948](#) DOI: [10.3389/fonc.2022.903016](#)]
- 22 **Wheatley SP**, Altieri DC. Survivin at a glance. *J Cell Sci* 2019; **132** [PMID: [30948431](#) DOI: [10.1242/jcs.223826](#)]
- 23 **Jia H**, Zhang X, Liu X, Qiao R, Liu Y, Lv S, Zhu H, Wang J, Kong Q, Zhang H, Zhang Z. FABP5, a Novel Immune-Related mRNA Prognostic Marker and a Target of Immunotherapy for Multiple Myeloma. *Front Med (Lausanne)* 2021; **8**: 667525 [PMID: [34249967](#) DOI: [10.3389/fmed.2021.667525](#)]
- 24 **Field CS**, Baixauli F, Kyle RL, Puleston DJ, Cameron AM, Sanin DE, Hippen KL, Loschi M, Thangavelu G, Corrado M, Edwards-Hicks J, Grzes KM, Pearce EJ, Blazar BR, Pearce EL. Mitochondrial Integrity Regulated by Lipid Metabolism Is a Cell-Intrinsic Checkpoint for Treg Suppressive Function. *Cell Metab* 2020; **31**: 422-437.e5 [PMID: [31883840](#) DOI: [10.1016/j.cmet.2019.11.021](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

